Stock Markets March 12, 2026

Halma Maintains FY26 Targets as Acquisition Drive Accelerates

Safety-equipment and sensor maker reports robust order intake and significant M&A spend while reiterating mid-teens organic growth outlook

By Jordan Park
Halma Maintains FY26 Targets as Acquisition Drive Accelerates

Halma plc said it is on course to meet its upgraded fiscal 2026 guidance, citing order intake that remains ahead of year-to-date revenue and the prior year. The company completed five acquisitions in FY26, spending a maximum consideration of A3451 million - roughly A3300 million more than in FY25 - and reiterated expectations for mid-teens organic constant currency revenue growth, an EBITA margin of about 22% excluding a one-off Nuvonic benefit, and roughly 90% cash conversion.

Key Points

  • Order intake is tracking ahead of year-to-date revenue and the prior year, with additional strength in H2 FY26.
  • Halma completed five acquisitions in FY26, spending up to A3451 million, about A3300 million more than in FY25; the M&A pipeline remains healthy across all three sectors.
  • FY26 guidance reiterated: mid-teens organic constant currency revenue growth, an EBITA margin of about 22% excluding a one-off Nuvonic benefit, and roughly 90% cash conversion.

Halma plc confirmed on Thursday that it continues to track in line with the upgraded expectations it set out alongside its first-half fiscal 2026 results. The safety equipment and sensor manufacturer said order intake is progressing ahead of both year-to-date revenue and the same period last year, with the second half of FY26 showing further strong momentum.

During FY26 the company completed five acquisitions, three of which closed in the second half of the year. On a maximum consideration basis, the total acquisition spend for the year was A3451 million. Management said this represented an increase of approximately A3300 million in M&A expenditure versus FY25.

Halma indicated its pipeline of acquisition targets remains healthy across all three of its operating sectors, and noted its most recent deal was the bolt-on purchase of Altomed, a UK-based business.

For the full year, management reiterated guidance that assumes mid-teens organic revenue growth on a constant currency basis, an EBITA margin of roughly 22% when excluding a one-off benefit from Nuvonic, and cash conversion of approximately 90%.

The company also flagged foreign exchange as a headwind for FY26, estimating an adverse impact on revenue of about A363 million and on EBITA of around A314 million.


Context and takeaways

  • Order intake remains above both year-to-date revenue and the prior year, with additional strength reported in the second half of FY26.
  • Five acquisitions were completed during FY26 with a maximum consideration of A3451 million, an increase of approximately A3300 million compared with FY25.
  • Management reiterated FY26 targets: mid-teens organic constant currency revenue growth, an adjusted EBITA margin of about 22% excluding a one-off Nuvonic benefit, and about 90% cash conversion.

The companys continued M&A activity, combined with ongoing order momentum, are central to the outlook management has reiterated. Foreign exchange movements, meanwhile, are expected to subtract roughly A363 million from revenue and about A314 million from EBITA in FY26.


What remains uncertain

  • Foreign exchange effects - management estimates a negative impact of approximately A363 million to revenue and A314 million to EBITA for FY26.
  • EBITA margin reporting is presented excluding a one-off benefit from Nuvonic; the stated margin of about 22% depends on that exclusion.
  • M&A scale - the companys FY26 maximum consideration of A3451 million was about A3300 million higher than FY25, creating variability associated with integration and future capital allocation.

Risks

  • Foreign exchange is expected to be a headwind to FY26 revenue and EBITA - approximately A363 million and A314 million respectively.
  • The reported EBITA margin of about 22% is stated excluding a one-off Nuvonic benefit, so the margin figure depends on that exclusion.
  • Significantly higher M&A expenditure in FY26 (maximum consideration of A3451 million, around A3300 million more than FY25) introduces uncertainty related to deal integration and capital allocation.

More from Stock Markets

Pharming Posts Q4 Revenue of $106.5m, Maintains 2026 Financial Targets Mar 12, 2026 Lightwave Logic Shares Spike After Development Pact With Tower Semiconductor Mar 12, 2026 Lilly warns of unknown impurity in compounded versions of its weight-loss drug Mar 12, 2026 Taiwan’s Major Parties Clear Way for Government to Sign U.S. Arms Agreements Ahead of Deadlines Mar 12, 2026 UK markets slip as oil tops $100; pound eases below $1.34 amid Middle East tensions Mar 12, 2026